Compare FBP & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBP | TMDX |
|---|---|---|
| Founded | 1948 | 1998 |
| Country | United States | United States |
| Employees | N/A | 898 |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | 2010 | 2019 |
| Metric | FBP | TMDX |
|---|---|---|
| Price | $20.83 | $93.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $24.13 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 1.5M | 924.9K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | 18.78 | ★ 382.18 |
| EPS | 2.15 | ★ 4.87 |
| Revenue | ★ $1,255,034,000.00 | $605,494,000.00 |
| Revenue This Year | $15.10 | $24.51 |
| Revenue Next Year | $4.56 | $18.73 |
| P/E Ratio | ★ $9.71 | $20.37 |
| Revenue Growth | 2.38 | ★ 37.13 |
| 52 Week Low | $16.40 | $62.42 |
| 52 Week High | $23.43 | $156.00 |
| Indicator | FBP | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 21.84 |
| Support Level | $20.41 | N/A |
| Resistance Level | $20.86 | $131.86 |
| Average True Range (ATR) | 0.49 | 5.71 |
| MACD | 0.08 | -2.76 |
| Stochastic Oscillator | 71.34 | 2.61 |
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.